Coronary heart disease, cerebrovascular disease, other atherosclerotic diseases, dyslipidemia
Conditions
Interventions
Original generic drug group:None
Original branded drug group:None
Group switching from branded to generic drug.:None
Group switching from generic to branded drug.:None
Sponsors
The First Affiliated Hospital of Wenzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. During the identification period (January 1st, 2020 – September 30th, 2025), having at least one prescription record for generic atorvastatin (Meidaxin) or the branded drug (Lipitor). 2. Continuous use of the same brand of atorvastatin for at least three months. 3. Aged 18–80 years at the date of first prescription in our hospital (T0).
Exclusion criteria
Exclusion criteria: 1. Use of any lipid-lowering medication within three months prior to the first prescription date. 2. Concomitant use of other lipid-lowering medications in addition to atorvastatin during the follow-up period. 3. Presence of abnormal daily dose values (atorvastatin daily dose >80 mg). 4. Patients with poor adherence to atorvastatin during the follow-up period [Proportion of Days Covered (PDC) <80%]. 5. Patients with no documented efficacy or safety outcome measures during the follow-up period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Liver function;Blood lipid levels; | — |
Secondary
| Measure | Time frame |
|---|---|
| Other adverse reactions;Cardiovascular and cerebrovascular events.; | — |
Countries
China
Contacts
Public ContactZhang Chunhong
The First Affiliated Hospital of Wenzhou Medical University
Outcome results
None listed